Recent evidence in the cow suggests that endothelin-1 (ET-1) plays a role during prostaglandin (PG) F 2␣ -induced luteal regression. We have examined the effects of treatment with PGF 2␣ during the early and midluteal phases on three components of the endothelin system: endothelin-converting enzyme-1 (ECE-1), ET type A receptor (ET A ), and ET-1 in the bovine corpus luteum (CL). Cyclic beef cows were injected (0 h) on Day 4 or 10 with either saline or the PGF 2␣ analogue Lutalyse (15 mg). The CL were collected at 2 (n ‫؍‬ 11), 10 (n ‫؍‬ 23), 24 (n ‫؍‬ 15), or 48 h (n ‫؍‬ 12) after treatment. The cows in which CL were removed after 10 h comprised of two experimental groups. The first group (n ‫؍‬ 11) received one injection; the second group (n ‫؍‬ 12) received two injections, one at 0 h and one at 8 h. The cows in which CL were collected after 24 and 48 h received one injection every 8 h. Semiquantitative reverse transcriptase-polymerase chain reaction was used to evaluate the mRNA encoding ECE-1, ET A , and ET-1. The ECE-1 and ET A proteins were evaluated by semiquantitative Western blot analysis. The ET-1 was the most likely component of the endothelin system target for PGF 2␣ regulation during the midluteal phase. The ET A and ECE-1 genes were constitutively expressed in the Day 4 and Day 10 CL. A practical application of this observation is that it may be possible to target the ET-1 gene as a way to manipulate the luteolytic action of PGF 2␣ .
INTRODUCTION
Progesterone (P 4 ), secreted by the corpus luteum (CL), is essential for the maintenance of pregnancy in the cow. When normal pregnancy occurs, the CL continues to secrete P 4 throughout pregnancy. If pregnancy does not occur, the CL undergoes luteolysis, P 4 secretion declines, and consequently, the next ovarian cycle occurs [1, 2] .
Luteolysis is brought about by the direct actions of prostaglandin (PG) F 2␣ on the CL. A combination of PGF 2␣ -induced changes result in cessation of luteal P 4 production and involution of luteal tissues with luteal cell death [3] [4] [5] . The luteolytic actions of PGF 2␣ are mediated by specific plasma membrane receptors that belong to the seven trans-membrane G protein-coupled superfamily [6] [7] [8] [9] [10] . Luteal regression might involve endocrine as well as paracrine/ autocrine actions of PGF 2␣ [3, 5] .
Interestingly, for those species in which PGF 2␣ is luteolytic, the early CL is resistant to the luteolytic actions of PGF 2␣ . Insensitivity to PGF 2␣ has been observed in cows [11] [12] [13] [14] , marmoset monkeys [15] , pigs [16] , and rats [17] . The mechanisms responsible for this insensitivity of early CL to the luteolytic actions of PGF 2␣ are poorly understood; however, this insensitivity is not due to the lack of highaffinity receptors for PGF 2␣ [6, 18, 19] . Indeed, recently, it has become clear that PGF 2␣ can regulate cellular and molecular processes, such as ascorbic acid depletion and inhibition of mRNA for steroidogenic enzymes and PG receptors in CL at the early and midluteal phase [20] .
Clearly, luteolysis is a complex process involving changes in the expression of many genes in at least three cell populations of the CL: the large and small steroidogenic cells, and the endothelial cells [21] [22] [23] [24] . Reports have appeared that either natural luteolysis or treatment with PGF 2␣ may decrease or increase mRNA encoding several pertinent genes [20] .
Recent evidence in the cow suggests that endothelin-1 (ET-1) plays an essential role during PGF 2␣ -induced luteal regression [23] . Both ET-1 mRNA and peptide were elevated within 2 h after in vivo or in vitro treatment with PGF 2␣ [25, 26] . High concentrations of ET-1 inhibit P 4 production by luteal cells [23] . The inhibitory effects of ET-1 have been shown to be exerted via the selective ET type A receptors (ET A ) [25] . Indeed, administration of PGF 2␣ during the midluteal phase induced both ET-1 and ET A [21] . In contrast, during the early luteal phase, administration of PGF 2␣ did not alter the expression of ET-1 and ET A [21] . These observations led Levy et al. [21] to suggest that the lack of ET-1 synthesis and response during the early luteal phase may render early CL insensitive to PGF 2␣ .
A 21-amino acid peptide, ET-1 is a member of the endothelin family that includes ET-2 and ET-3 [27] . Endothelins are initially synthesized as 203-amino acid precursor proteins, called preproETs (ppET), that are first proteolytically cleaved to generate big ETs and are then processed to the active peptides via an endothelin-converting enzyme (ECE) [28, 29] . ECE-1 is the key enzyme in cleaving the inactive, big ET-1 at the Trp 21 /Val 22 bond for its conversion to the active ET-1 peptide [30, 31] . In fact, ECE-1 has been shown to be present in both endothelial and steroidogenic cells of the bovine CL [32] .
The ETs act on at least two distinct ET receptor subtypes of the seven transmembrane G protein-coupled receptors: ET A , and ET type B receptor (ET B ). Both ET-1 and ET-2 bind to ET A with higher affinity than ET-3 [33] . However, ET B binds all three isopeptides with equal affinity [34] . In 5Ј-TCATGAAGTGTGACGTTGACATCCGT-3Ј  5Ј-CCTAGAAGCATTTGCGGTGCACGATG-3Ј  5Ј-GATGGTGATGTTGGCCAGCG-3Ј  5Ј-GGGAACACAACCAGGCCATC-3Ј  5Ј-TGTTCCAGTATGATTCCACCC-3Ј  5Ј-TCCACCACCCTGTTGCTGTA-3Ј  ET A   ET-1   Sense:  Antisense:  Sense:  Antisense:   5Ј-TTCTACTTCTGCATGCCCCTGGT-3Ј  5Ј-GTCCTTGTGGCTGCTCCTCTCAG-3Ј  5Ј-TGTCTTCATCAGCAGCTCG-3Ј  5Ј-GTTTCTCCCTGAAATGTGCC-3Ј the cow, ET A has been identified in CL at the midluteal phase [25] . The ET A mRNA expression was demonstrated on small and large luteal cells and on endothelial cells of the bovine CL [23] .
In the present study, we have examined the effects of administration of PGF 2␣ during the early and midluteal phases on the mRNA expression encoding ECE-1, ET A , and ppET-1 and on the amounts of ET A and ECE-1 protein in bovine CL.
MATERIALS AND METHODS

Treatments and Tissue Collection
Cyclic beef cows were treated on Day 4 (n ϭ 31) or Day 10 (n ϭ 30) with either saline or PGF 2␣ (15 mg; Lutalyse; Pharmacia and Upjohn, Inc., Kalamazoo, MI). Ovaries were collected by blunt dissection after ovariectomy via supravaginal incision under epidural anesthesia (6-9 ml of 2% lidocaine for cows weighing 450-700 kg) [35, 36] . The ovaries were removed at 2 (n ϭ 11), 10 (n ϭ 23), 24 (n ϭ 15), or 48 h (n ϭ 12). The experimental group in which the ovaries were removed at 2 h received a single injection. The cows in which the ovaries were removed at 10 h included two experimental groups: one that received a single injection at time zero (0 h, n ϭ 11), and one that received two injections (one at 0 h and one at 8 h). The experimental groups in which the ovaries were collected at 24 and 48 h received an injection every 8 h. The CL were immediately dissected from the collected ovaries, frozen in liquid nitrogen, and stored at Ϫ70ЊC. Protocols for all animal experiments described in this study were approved by the West Virginia University Animal Care and Use Committee.
Total RNA Isolation and Primer Design
Total RNA was isolated from tissue samples with Trizol reagent according to the manufacturer's instructions (Gibco BRL, Gaithersburg, MD). The RNA was quantified spectroscopically at 260 nm. The primers for ECE-1 (Table 1) were designed based on known DNA sequences of human and bovine ECE-1 and generated a 500-base pair (bp) polymerase chain reaction (PCR) product. The 500-bp ECE-1 cDNA was sequenced (Davis Sequencing, Davis, CA) and verified to represent genuine ECE-1␣ isoform. The sequence was used to search the nucleic acid database at the National Center for Biotechnology Information (NCBI) with the BLAST software [37] . The ET A primers (Table 1) were designed based on known ET A DNA sequences. The PCR product generated for ET A was 500 bp. It was sequenced (Davis Sequencing) and verified to represent genuine ET A receptor via NCBI BLAST [37] . The primers for ET-1 were those designed by Levy et al. [21] . These primers (Table 1) have been verified to amplify genuine ET-1 [21] . We have used their sequence to search the nucleic acid database at NCBI with the BLAST software [37] and corroborated their specificity. Primers for two constitutively expressed genes, ␤-actin (Promega, Madison, WI) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were used as internal standards (Table 1) .
Semiquantitative Reverse Transcriptase-PCR
Semiquantitative reverse transcriptase (RT)-PCR assays were performed using the OneStep RT-PCR Kit (Qiagen, Valencia, CA). The parameters for the RT-PCR assays were optimized for semiquantitative analysis of expression of ECE-1, ET A , ET-1, ␤-actin, and GAPDH transcripts in the bovine CL.
The number of cycles for ECE-1 was tested in the range of 20-30 cycles with a total RNA concentration of 600 ng/l (data not shown). Total RNA concentration for ECE-1 and ␤-actin was tested in the range of 5-50 ng/l (data not shown). When optimal parameters were determined for ECE-1 and ␤-actin, the RT-PCR assays were performed at 50ЊC for 30 min for reverse transcription reaction and at 95ЊC for 15 min for activation of RT-PCR enzyme. Thirty cycles were carried out as follows: 94ЊC for 30 sec for denaturing, 52ЊC for 1 min for annealing, and 72ЊC for 1 min for extension, followed by a 10-min final extension at 72ЊC. The ␤-actin housekeeping gene was determined to be beyond the linear range for the optimal total RNA concentration for ET A (data not shown). Therefore, GAPDH was used as the internal standard for ET A .
The number of cycles for ET A was tested in the range of 20-28 cycles at 600 ng/l (data not shown). Total RNA concentration for ET A and GAPDH was tested in the range of 30-600 ng/l (data not shown). When optimal parameters were determined, the RT-PCR assays were performed using 50ЊC for 30 min for reverse transcription reaction and 95ЊC for 15 min for activation of RT-PCR enzyme. Twenty-five cycles for GAPDH and 28 cycles for ET A were carried out as follows: 94ЊC for 50 sec for denaturing, 52ЊC for 1 min for annealing, and 72ЊC for 1 min for extension, followed by a 10-min final extension at 72ЊC.
The number of cycles for ET-1 was tested in the range of 20-30 cycles at 100 ng/l (data not shown). When optimal parameters were determined, the RT-PCR assays were performed using 50ЊC for 30 min for reverse transcription reaction and 95ЊC for 15 min for activation of RT-PCR enzyme. Twenty-six cycles for GAPDH and 30 cycles for ET-1 were carried out as follows: 94ЊC for 50 sec for denaturing, 52ЊC for 1 min for annealing, and 72ЊC for 1 min for extension, followed by a 10-min final extension at 72ЊC.
All PCR products were electrophoresed on 2% agarose gel, stained with ethidium bromide, and viewed using the Fluor-S MultiImager (BioRad Laboratories, Hercules, CA). Data were collected using the densitometric analysis of the Quantity One quantitation software package (version 4.0; Bio-Rad Laboratories).
Western Blotting Analyses of ECE-1 and ET A
Protein samples from saline-and PGF 2␣ -treated, Day 4 and Day 10 bovine CL collected after 24 and 48 h were obtained from the tissues collected as described in Treatments and Tissue Collection. Proteins were isolated from individual bovine CL using the Trizol reagent as specified by the manufacturer. Protein concentration in the samples was determined with the Bio-Rad Protein Assay. The optimal protein concentration needed to detect ECE-1, ET A , and actin was determined by testing 5, 10, 20, 50, and 100 g of isolated proteins from the CL.
The SDS-PAGE was carried out as previously described [38] . Briefly, protein samples were loaded onto an 8% polyacrylamide gel. After electrophoresis at 150 V for 1 h, the resolved proteins were transferred to polyvinylidene fluoride membranes (Biotechnology Systems, Boston, MA) using a Mini-V 8.10 Blot Module (Gibco BRL). The membranes were blocked in 1% BSA with 0.05% Tween-20 in Tris-buffered saline (TBS-T, pH 7.5) for 2 h at room temperature. The membranes were incubated with the primary antibody for 2 h at room temperature and washed three times for 10 min in TBS-T. Subsequently, the membranes were incubated with anti-rabbit (1:5000 [v/v]; Amersham Pharmacia Biotech, Piscataway, NJ) or anti-mouse (1:30 000 [v/v]; Gibco, Grand Island, NY) horse radish peroxidase-conjugated antibodies for 1 h. After three TBS-T washes, visualization was achieved using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech) and Kodak Biomax Light Film (Eastman Kodak Company, Rochester, NY). This technology was selected because of its versatility in allowing the stripping of primary and secondary antibodies from membranes for sequential reprobing of membranes with a variety of antibodies.
Stripping of membranes was performed with Restore Western Blot Stripping Buffer (Pierce, Rockport, IL). Stripping conditions were tested to demonstrate complete removal of antibodies, and 1 h at room temperature was found to be effective for all antibodies used in this study. Sequential reprobing with the same antibody demonstrated that the signal intensity did not decrease during up to five strippings of the membranes (data not shown). Images of the detected proteins were captured using the Fluor-S MultiImager. Densitometry of the bands of interest were performed using the Quantity One quantitation software. The intensity of the signal corresponding to the ECE-1 and ET A proteins were standardized by the corresponding intensity of the actin protein control. This normalization of data allowed us to estimate, in a semiquantitative manner, the amount of protein in the sample of interest. This semiquantitative Western blot methodology has been described earlier [39] . Three primary antibodies were used in these studies. A mouse anti-actin monoclonal antibody (Chemichon International, Inc., Temecula, CA) was used at a dilution of 1:3000 (v/v). The rabbit anti-ET A polyclonal antibody (Chemichon International, Inc.) was used at a dilution of 1:200 (v/v). The rabbit polyclonal anti-bovine ECE-1 antibody (a generous gift of Dr. Masashi Yanagisawa from the Howard Hughes Medical Institute, University of Texas Southwestern Medical Institute, Dallas, TX) was used at a dilution of 1:2000 (v/v). The specificity of each primary antibody was confirmed using antibody-specific epitope peptides preincubated with the primary antibody before addition to membranes.
Statistical Analysis
Statistical analyses were performed using JMP, a statistical software program for the Apple Macintosh [40] . For the RT-PCR, semiquantification was based on the ratios of the densitometric analyses of ECE-1 to ␤-actin and of ET A to GAPDH. Thirty-one samples were used for Day 4, and 30 samples were used for Day 10. The average values for each time point were calculated, and saline control versus PGF 2␣ treatments were compared. For the Western blot analysis, semiquantification was based on the ratios of the densitometric analyses of ECE-1 and ET A to actin. Fifteen samples were used for Day 4, and 12 samples were used for Day 10. The average values for each time point were calculated, and saline controls versus PGF 2␣ were compared. Data are presented as the mean Ϯ SEM. Statistical significance was determined using the Student t-test [40] .
RESULTS
Detection of ECE-1, ␤-Actin, ET A , ET-1, and GAPDH Transcripts in Bovine CL
The validity of the RT-PCR assays for semiquantitative evaluation was supported by at least three criteria: 1) by selecting, for each target, an RNA concentration yielding amplification in the exponential phase of the RT-PCR (data not shown); 2) by repetitive observations of results within experimental groups (at least two assays per data point); and 3) by using an appropriate standard control.
The RT-PCR assays were optimized for semiquantitative analysis of expression of ECE-1, ␤-actin, ET A , ET-1, and GAPDH transcripts in bovine CL. In the case of ECE-1, plotting the intensity of the RT-PCR signal (as expressed by absolute optical density values) against the number of amplification cycles revealed a linear relationship between cycles 24 and 30 (r 2 ϭ 0.61; data not shown). The PCR products generated for ␤-actin and ECE-1 were 285 and 500 bp, respectively, with primer pairs 1 and 2 ( Table 1) . The 500-bp band was sequenced and shown to be genuine ECE-1 (data not shown). The intensity of the band produced with the primer pair corresponding to ␤-actin was stronger than the one produced with the primer pair corresponding to ECE-1. However, the intensity of the bands produced was well correlated with the amount of total RNA tested (range, 5-50 ng). Based on this finding, in subsequent RT-PCR experiments, the total RNA concentration used to evaluate the expression of these two genes was selected at 10 ng. The number of cycles for the RT-PCR was fixed at 30 cycles, and under these conditions, the level of expression of both genes was in the linear range.
The amount of gene expression for ␤-actin was much greater than that for the ET A (data not shown). The GAPDH gene was a better internal standard than ␤-actin when evaluating the amount of mRNA encoding the ET A . As expected, the primer pairs designed for GAPDH and ET A (primer pairs 3 and 4) ( Table 1 ) generated RT-PCR products of 900 and 500 bp, respectively. These RT-PCR products were sequenced and shown to represent genuine ET A and GAPDH (data not shown). The optimal number of cycles for ET A was fixed at 28, because a good correlation was found between the signal generated when the cycles were tested from 22 to 28 cycles (r 2 ϭ 0.60). Because the GAPDH gene was expressed at a higher number of copies than the ET A gene (data not shown), the number of cycles for GAPDH was selected at 25. When optimizing the RT-PCR conditions for ET A and GAPDH, good correlation was found (ET A , r 2 ϭ 0.64; GAPDH, r 2 ϭ 0.61) between the intensity of the bands produced and the amount of total RNA used (range, 30-600 ng). The primer pair for ET-1 generated a RT-PCR product of 580 bp. The optimal number of cycles determined was 30 [41, 42] by their respective antibodies. Based on this finding, we chose 30-g protein samples to evaluate the effect of PGF 2␣ on the amount of these proteins in the samples. The specificity of ET A antibody was confirmed by preabsorption of the antibody with excess peptide (data not shown). The specificity of the bands detected with the ECE-1 and actin antibodies have been similarly confirmed elsewhere [41, 42] .
Effect of PGF 2␣ on Luteal ECE-1 mRNA
The amounts of luteal mRNA encoding ECE-1, ET A , and ET-1 were evaluated in the early and midluteal phase of the cycle at 2 and 10 h after a dosage of 15 mg of PGF 2␣ . The sensitivity of the early and midluteal CL was evaluated further by the response to repeated injections of 15 mg of PGF 2␣ every 8 h.
As reported elsewhere [43] , the concentration of PGF 2␣ used in this study was effective in reducing plasma concentration of P 4 in Day 4 and Day 10 CL. Figure 1A Figure 1C shows that, in the early CL, PGF 2␣ treatment had no effect on the amount of mRNA encoding ECE-1 at any time point examined (P Ͼ 0.1). After 48 h, a slight decrease was observed in the amount of ECE-1 mRNA, but this difference was not statistically significant from its saline control. This finding was also seen at the protein level.
During the midluteal phase of the cycle, one or multiple injections of PGF 2␣ had no effect on the amount of mRNA encoding ECE-1 up to 10 h (P Ͻ 0.05) (Fig. 1C) . In contrast, after 24 h, PGF 2␣ had induced a significant (P ϭ 0.05), 20% reduction in the amount of ECE-1 mRNA. By 48 h, this PGF 2␣ -induced inhibition was more pronounced (ϳ60%, P Ͻ 0.01). This effect of PGF 2␣ was also observed in the amount of ECE-1 protein. Figure  3C shows that, in the early CL, PGF 2␣ treatment had no effect on the amount of mRNA encoding ET-1 at any time point examined (P Ͼ 0.1). During the midluteal phase of the cycle, a single injection of PGF 2␣ had no effect on the amount of mRNA encoding the ET-1 up to 10 h. In the midluteal CL collected after 10 h, the two injections of PGF 2␣ induced a statistically significant (P Ͻ 0.05), 55% increase in the amount of mRNA encoding ET-1. By 24 h, the amount of ET-1 mRNA was increased 66%, but this increase was not statistically significant. After 48 h, the amount of ET-1 mRNA was increased by approximately 54% (P ϭ 0.059) from the saline control.
Effect of PGF 2␣ on Luteal ECE-1 Protein Concentration
In the early CL, PGF 2␣ treatment had no effect on the amount of ECE-1 protein at any time point examined (P Ͼ 0.1) (Fig. 4A) . During the midluteal phase of the cycle, only the 48-h treatment with PGF 2␣ induced a statistically significant (P Ͼ 0.01), 12% reduction in the amount of ECE-1 protein (Fig. 4A) . In the 24-h treatment group, PGF 2␣ had no effect on the amount of ECE-1 protein (P Ͼ 0.9) (Fig. 4A) .
Effect of PGF 2␣ on Luteal ET A Protein Concentration
Administration of PGF 2␣ did not affect the amount of ET A protein at any time point examined for Day 10 (Fig.  4B) or Day 4 CL. Surprisingly, no statistical differences were observed in the amount of ET A protein present in the Day 4 CL from the amount detected in the Day 10 CL (Fig.  4B) . Figure 5 shows representative Western blots corresponding to the 48-h treatment for Day 10 ( Fig. 5A ) and Day 4 (Fig. 5B) CL. Protein bands of 130, 57, and 43 kDa were immunodetected with the antibodies for ECE-1, ET A , and actin, respectively.
DISCUSSION
In these studies, we have demonstrated a novel action of PGF 2␣ during the midluteal phase of the bovine CL: It regulates the amount of mRNA encoding ECE-1. This novel luteal action for PGF 2␣ appears to be inhibitory in nature. It was first observed after 24 h in CL of cows that received multiple injections of PGF 2␣ . Importantly, this novel action of PGF 2␣ was cycle-phase specific, because it was not observed in the early CL. This finding supports and expands the work by Meidan and Levy [32] , who reported the expression of ECE in the bovine CL.
This observation implies that a PGF 2␣ -mediated up-reg- ulation of the ECE-1 gene is not required for PGF 2␣ to upregulate ET-1 during the midluteal phase. In fact, we observed a down-regulation of ECE-1 mRNA and protein by PGF 2␣ . Evidently, the amount of ECE-1 mRNA and protein were not different between the Day 4 and Day 10 CL. Furthermore, PGF 2␣ , in a phase-specific fashion, down-regulates the expression of this gene in the Day 10 CL. This phase-specific action of PGF 2␣ on the ECE-1 gene is unlikely to contribute to the complex mechanism responsible for the insensitivity of early CL to the luteolytic actions of PGF 2␣ . A more likely candidate gene would be the phasespecific action of PGF 2␣ on ppET-1 mRNA, as observed in this study and reported by Levy et al. [21] . This later observation by Levy et al. [21] , corroborated in the present study, supports the proposed participation of endothelin in mediating the luteolytic actions of PGF 2␣ in the CL. The mechanism responsible for the resistance observed in the early CL to the luteolytic actions of PGF 2␣ is not fully understood, but several potential components have been implicated. Silva et al. [44] recently demonstrated that luteal prostaglandin dehydrogenase (PGDH) activity in the CL of the ewe is greater on Day 3 than on Day 13 of the estrous cycle. The PGDH is responsible for converting PGF 2␣ to its inactive metabolite; therefore, its higher activity in the early CL could account for lower intraluteal concentrations of PGF 2␣ in the early CL, leading to its resistance. Tsai et al. [18] as well as Tsai and Wiltbank [45] have reported that a single injection of PGF 2␣ up-regulated mRNA encoding prostaglandin G/H synthase 2 (PGHS-2, COX 2) in the mid-and late-cycle ovine and bovine CL, but that it was not effective in animals on Day 4 of the estrous cycle. Therefore, these investigators proposed that secretion of PGF 2␣ by late-cycle CL amplified the luteolytic signal from the uterus in an autocrine/paracrine manner [45] . Because this amplification is not observed in the early CL, this could account for its resistance to the luteolytic actions on PGF 2␣ . In contrast, Sayre et al. [43] found that repeated treatment with PGF 2␣ up-regulated PGHS-2 and PGF 2␣ synthase in Day 4 CL.
Levy et al. [21] have reported another possible cause for the resistance of early CL. These investigators have stated that administration of PGF 2␣ during the early bovine luteal phase does not alter expression of ET-1 or ET A . In contrast, ET-1 and ET A mRNA were markedly induced during the midluteal phase of the CL when exposed to a similar dose of PGF 2␣ .
Although we detected a higher amount of mRNA encoding ET A in Day 10 than in he Day 4 CL, this was not the case at the protein level. Furthermore, we failed to detect any regulatory effect by PGF 2␣ on this gene at the mRNA and protein level. This observation contrasts with that of Levy et al. [21] , who found that PGF 2␣ administered during the midluteal phase was able to induce both ET-1 and ET A . These investigators also reported that, during the early luteal phase, administration of PGF 2␣ did not alter the expression of the ET A [21] . We examined CL at 2, 10, 24, and 48 h and multiple challenges with PGF 2␣ , but we never observed a stimulatory effect on this gene by PGF 2␣ in the Day 4 or Day 10 bovine CL. The reason for this discrepancy is not clear. However, in the study by Levy et al. [21] , the dairy cows used for the midluteal stage varied from Day 10 to Day 17. If their midluteal samples were closer to Day 17, the luteal tissue could possibly have developed greater PGF 2␣ sensitivity. Our observation would imply that the mRNA encoding ET A is up-regulated from levels observed on Day 4 to those seen on Day 10 by PGF 2␣ -independent mechanisms. However, as mentioned earlier, this was not translated into a greater amount of ET A protein.
Although we never observed a stimulatory effect on the ET A gene by PGF 2␣ , we did not see any inhibitory effect, even after 48 h with multiple injections. Clearly, this gene is regulated very differently than the ECE-1 gene. The results of our studies indicate that if the ET system mediates the luteolytic action of PGF 2␣ , an up-regulation of the ET system from the Day 4 to the Day 10 CL does not require an increased expression of the ET A and ECE-1 genes by PGF 2␣ . However, as argued above, an increased sensitivity of the CL for PGF 2␣ to up-regulate these components of the endothelin system possibly is reached later than the luteal stages examined here. If ET-1 participates in mediating the luteolytic actions of PGF 2␣ , the gene expression of the ET A and ECE-1 do not appear to be the limiting factors of the CL endothelin system. Our observation that the amount of mRNA encoding ECE-1 is down-regulated by PGF 2␣ in the Day 10, but not in the Day 4, CL may be a result of the increased ET-1 by PGF 2␣ at these developmental stages of the CL. A similar finding has been reported in the vascular system of the rat pulmonary endothelial cells, in which ET-1 inhibits ECE-1 expression [46] .
Clearly, these actions of PGF 2␣ during the midluteal phase of the CL can be dissociated from its actions on P 4 . First, a single injection of PGF 2␣ during the midluteal phase of the CL, which effectively reduced the plasma concentration of P 4 , had no effect on the amount of mRNA encoding ECE-1 and ET-1 by 10 h. Second, multiple injections of PGF 2␣ in the early CL effectively reduced plasma levels of P 4 without any effect on mRNA encoding ECE-1 or ET-1. Unchanged mRNA concentrations for ECE-1 possibly were enough to maintain the necessary amount of bioactive ET-1. This is an issue that needs to be explored further in future studies. In fact, a reduction in mRNA encoding ECE-1 was detected after 24 h, but a reduction in the amount of ECE-1 protein was not detected until 48 h. It will be necessary to determine the effect of PGF 2␣ on the actual ECE-1 activity. Certainly, the amount of ppET-1 mRNA was increased by PGF 2␣ at a time when both ECE-1 mRNA and protein were reduced by the PGF 2␣ treatment. This increase in ppET-1 mRNA induced by PGF 2␣ also likely results in an increase in ET-1 peptide [47] . If so, then three scenarios can be envisioned. First, the observed reduction in ECE-1 mRNA possibly is not to a level at which the ECE-1 protein and activity would be reduced and become rate-limiting in the production of bioactive ET-1. Second, ECE-1 is not the enzyme responsible for generating bioactive ET-1 in the bovine CL. Third, an ECE-1 isoform different from the one that we have examined (i.e., ECE-1␣) is compensating for the reduced ECE-1 mRNA and protein. In the human vascular system, evidence indicates that, by alternative splicing, the ECE-1 gene can generate several ECE-1 isoforms [48] . At this time, we cannot distinguish among these possible interpretations.
If ET-1 participates in mediating the luteolytic actions of PGF 2␣ , then the results of our studies indicate that the ET-1 gene is the component of the endothelin system most likely to be involved with PGF 2␣ regulation. The ECE-1 and the ET A appear to be constitutively expressed in the Day 4 and Day 10 CL.
In summary, we report in this study a novel action of PGF 2␣ during the midluteal phase of the bovine CL: It regulates the amount of mRNA encoding ECE-1. This novel luteal action for PGF 2␣ appeared to be inhibitory in nature. Importantly, this novel action of PGF 2␣ was cycle-phase specific, because it was not observed in the early CL. We suggest that if ET-1 participates in mediating the luteolytic actions of PGF 2␣ , then the most likely component of the endothelin system in the bovine CL target for PGF 2␣ regulation is the ET-1 gene. Finally, an important practical implication of this observation is that it may be possible to target the ET-1 gene as an effective way to manipulate the luteolytic actions of PGF 2␣ .
